TO · EDT.TO · MEDICAL - DIAGNOSTICS & RESEARCH
Spectral Medical Inc. (EDT.TO) intrinsic value and stock valuation
$1.03as of 2026-11-21 · Mkt cap 416.65M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Spectral Medical Inc. DCF and intrinsic value
InvestorsCraft values EDT.TO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EDT.TO’s statements →
Spectral Medical Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.44M | $2.29M | $1.6M | $1.67M | $2M |
| Operating income | -$-11.69M | -$-12M | -$-11.42M | -$-8.45M | -$-6.66M |
| Net income | -$-47.69M | -$-15.4M | -$-15.66M | -$-11.28M | -$-8.79M |
| EPSd | -$-166.05K | -$-54.79K | -$-56.22K | -$-41.8K | -$-34.82K |
| Operating cash flow | -$-9.52M | -$-8.82M | -$-10.72M | -$-9.9M | -$-8.7M |
| Capital expenditure | -$-200K | -$-30K | -$-180K | -$-30K | -$-480K |
| Free cash flow | -$-9.72M | -$-8.85M | -$-10.91M | -$-9.93M | -$-9.18M |
| Total assets | $6.1M | $5.32M | $5.21M | $12M | $11.6M |
| Total debt | $21.1M | $14.9M | $8.56M | $7.57M | $580K |
| Net debt | $17M | $11.9M | $5.61M | -$-1.77M | -$-8.31M |
| Total equity | -$-69.72M | -$-27.55M | -$-16.55M | -$-2.55M | $4.08M |
| Cash and short-term investments | $4.07M | $2.99M | $2.95M | $8.41M | $8.89M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.44M | $2.29M | $1.6M | $1.67M | $2M |
| Cost of revenue | $7.6M | $1.27M | $940K | $680K | $830K |
| Gross profit | -$-5.16M | $1.02M | $660K | $980K | $1.16M |
| Research and development expenses | $4.33M | $3.97M | $4.68M | $0.00 | $0.00 |
| Selling, general and administrative expenses | $2.19M | $11.6M | $11.3M | $8.64M | $7.01M |
| Other expenses | $0.00 | -$-2.57M | $0.00 | $1.04M | $1.04M |
| Operating expenses | $6.53M | $13M | $12.1M | $9.43M | $7.86M |
| Cost and expenses | $14.1M | $14.3M | $13M | $10.1M | $8.65M |
| Interest income | $5.39M | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $5.16M | $3.18M | $1.33M | $180K | $30K |
| Depreciation and amortization | $250K | $250K | $220K | $270K | $290K |
| Ebitda | -$-11.44M | -$-11.97M | -$-13.96M | -$-7.18M | -$-6.38M |
| Operating income | -$-11.69M | -$-12M | -$-11.42M | -$-8.45M | -$-6.66M |
| Total other income/expenses, net | -$-36M | -$-3.4M | -$-4.09M | $820K | -$-40K |
| Income before tax | -$-47.69M | -$-15.39M | -$-15.51M | -$-7.63M | -$-6.96M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-47.69M | -$-15.4M | -$-15.66M | -$-11.28M | -$-8.79M |
| Weighted average shares outstanding | $287.2M | $281.1M | $278.6M | $269.8M | $252.5M |
| Weighted average diluted shares outstanding | $287.2M | $281.1M | $278.6M | $269.8M | $252.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.07M | $2.99M | $2.95M | $8.41M | $8.89M |
| Net receivables | $200K | $450K | $190K | $1.06M | $200K |
| Inventory | $380K | $230K | $370K | $340K | $290K |
| Total current assets | $5.29M | $4.46M | $4.12M | $10.1M | $10.3M |
| Property, plant and equipment, net | $470K | $690K | $890K | $700K | $1.06M |
| Goodwill and intangible assets | $330K | $170K | $190K | $210K | $230K |
| Long-term investments | $0.00 | $0.00 | $0.00 | $1M | $0.00 |
| Total non-current assets | $810K | $860K | $1.09M | $1.91M | $1.29M |
| Total assets | $6.1M | $5.32M | $5.21M | $12M | $11.6M |
| Accounts payable | $1.34M | $990K | $1.6M | $1.65M | $440K |
| Short-term debt | $16.6M | $14.6M | $390K | $3.66M | $90K |
| Deferred revenue | $690K | $380K | $730K | $700K | $690K |
| Total current liabilities | $66.3M | $27.5M | $10.2M | $6.63M | $2.3M |
| Long-term debt | $4.52M | $370K | $8.18M | $3.91M | $490K |
| Deferred revenue, non-current | $4.56M | $5.05M | $3.34M | $4.01M | $4.68M |
| Total non-current liabilities | $9.55M | $5.42M | $11.5M | $7.92M | $5.17M |
| Capital lease obligations | $230K | $500K | $620K | $520K | $580K |
| Total liabilities | $75.8M | $32.9M | $21.8M | $14.6M | $7.47M |
| Common stock | $95.9M | $90.6M | $87.1M | $87.1M | $84.4M |
| Retained earnings | -$-188.53M | -$-140.84M | -$-125.44M | -$-109.78M | -$-98.49M |
| Accumulated other comprehensive income (loss) | $12.7M | $12.6M | $12.9M | $11.4M | $10.2M |
| Total equity | -$-69.72M | -$-27.55M | -$-16.55M | -$-2.55M | $4.08M |
| Total investments | $0.00 | $0.00 | $0.00 | $1M | $0.00 |
| Total debt | $21.1M | $14.9M | $8.56M | $7.57M | $580K |
| Net debt | $17M | $11.9M | $5.61M | -$-1.77M | -$-8.31M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $0.00 | -$-15.39M | -$-15.66M | -$-11.25M | -$-8.79M |
| Depreciation and amortization | $250K | $250K | $220K | $270K | $290K |
| Stock-based compensation | $0.00 | $1.68M | $1.49M | $1.2M | $1.26M |
| Change in working capital | -$-190K | $1.01M | -$-410K | $580K | -$-1.76M |
| Accounts receivable | $250K | -$-270K | $870K | -$-880K | $60K |
| Inventory | -$-150K | $140K | -$-30K | -$-50K | -$-50K |
| Accounts payable | -$-270K | -$-50K | -$-270K | $1.65M | -$-1.1M |
| Net cash provided by operating activities | -$-11.63M | -$-8.82M | -$-10.72M | -$-9.9M | -$-8.7M |
| Investments in property, plant and equipment | -$-200K | -$-30K | -$-180K | -$-30K | -$-480K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-200K | -$-30K | -$-180K | -$-30K | -$-330K |
| Common stock issued | $3.4M | $1.15M | $0.00 | $4.03M | $10M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $12.9M | $8.88M | $5.44M | $9.46M | $12.2M |
| Net change in cash | $1.08M | $40K | -$-5.46M | -$-480K | $3.08M |
| Cash at end of period | $4.07M | $2.99M | $2.95M | $8.41M | $8.89M |
| Operating cash flow | -$-9.52M | -$-8.82M | -$-10.72M | -$-9.9M | -$-8.7M |
| Capital expenditure | -$-200K | -$-30K | -$-180K | -$-30K | -$-480K |
| Free cash flow | -$-9.72M | -$-8.85M | -$-10.91M | -$-9.93M | -$-9.18M |
Line items
Line items
Line items
About Spectral Medical Inc.
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
- CEO
- Christopher Seto
- Employees
- 29
- Beta
- 0.17
Explore
Frequently asked questions
What is the intrinsic value of Spectral Medical Inc. (EDT.TO)?
InvestorsCraft does not currently publish an intrinsic value for EDT.TO. How the IC value is calculated.
Is EDT.TO undervalued?
InvestorsCraft does not publish an undervaluation signal for EDT.TO at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.